Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer

William J. Gradishar, Everett E. Vokes*, Merrill S. Kies

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In an effort to improve the response rate of patients with advanced head and neck cancer, a clinical trial combining two infrequently studied drugs was conducted. Twelve patients with squamous cell carcinoma of the head and neck were treated with 3‐day continuous infusions of etoposide (90 mg/m2/day) and doxorubicin (15 mg/m2/day). All patients had been heavily pre‐treated with surgery, radiation therapy, and/or chemotherapy. No objective responses were observed in 9 evaluable patients. One patient maintained stable disease state for 4 months. The major toxicity was Grade 3 or 4 myelosuppression which occurred in 42% of administered cycles. Although single‐agent etoposide and doxorubicin have shown response rates of 10%‐40% in patients with squamous cell carcinoma of the head and neck, we were disappointed to find that the combination of etoposide and doxorubicin has little or no activity in patients with advanced head and neck cancer. The toxicity encountered with this combination was significant.

Original languageEnglish (US)
Pages (from-to)487-490
Number of pages4
JournalMedical and Pediatric Oncology
Volume18
Issue number6
DOIs
StatePublished - Jan 1 1990

Keywords

  • VP‐16
  • adriamycin
  • head and neck cancer

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer'. Together they form a unique fingerprint.

Cite this